Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis.
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_ADD6E18857F6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis.
Journal
Annals of transplantation
ISSN
2329-0358 (Electronic)
ISSN-L
1425-9524
Publication state
Published
Issued date
13/11/2018
Peer-reviewed
Oui
Volume
23
Pages
789-801
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study
Publication Status: epublish
Publication Status: epublish
Abstract
BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis B virus (HBV) infection after liver transplantation using hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogue (NUC) prophylaxis. MATERIAL AND METHODS Data from 371 adults transplanted for HBV-related disease at 20 European centers and given HBIg for ³12 months ± NUC therapy were analyzed retrospectively. RESULTS HBIg comprised Hepatect® (iv HBIgB; n=299), subcutaneous Zutectra® (sc HBIg, n=236), and other HBIg preparations (n=130); 93.5% received NUC therapy. Mean follow-up was 6.8±3.5 years. The primary efficacy variable, freedom from HBV recurrence, occurred in 95.7% of patients (95% CI [93.1%, 97.5%]). The observed incidence of recurrence was 16/371 (4.3%) (annual rate 0.65%); 5/16 patients with recurrence had discontinued HBIg and 7/16 had anti-HBs <100 IU/l. Excluding these 7 patients, the HBV recurrence rate was 2.4%. The recurrence rate while on HBIg therapy was 1 per 2069 months. In patients who discontinued HBIg, risk of HBV recurrence versus sc HBIg users was increased by 5.2-fold (1 per 1 603 versus 1 per 8379 treatment months). The annual rate of HBV-related hepatocellular carcinoma (HCC) recurrence was 1.7%. CONCLUSIONS These results support the long-term use of HBIg with NUC therapy as an effective management strategy to minimize risk of HBV recurrence and virus-related complications after liver transplantation.
Keywords
Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents/therapeutic use, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis B, Chronic/prevention & control, Hepatitis B, Chronic/surgery, Humans, Immunoglobulins/therapeutic use, Liver Transplantation, Male, Middle Aged, Nucleosides/therapeutic use, Recurrence, Retrospective Studies, Secondary Prevention/methods, Treatment Outcome, Young Adult
Pubmed
Web of science
Create date
13/12/2018 13:09
Last modification date
14/09/2021 5:40